Inflammasome Target Adiso is developing ADS032, a dual NLRP1 and NLRP3 inflammasome inhibitor, offering a differentiated mechanism for inflammatory diseases which may align with partners seeking novel inflammasome modulation therapies.

Live Biotherapeutic ADS024 is a single strain live biotherapeutic product with a unique mechanism, presenting a potential collaboration or licensing opportunity for companies exploring microbiome-based approaches to inflammation.

Funding & Growth With around $60M in funding and ongoing programs from discovery to early-phase trials, Adiso could be a target for co-development, strategic investments, or milestone-based partnerships to accelerate clinical timelines.

Board Expansion Recent board addition signals growth and governance maturation, suggesting readiness for larger partnerships, licensing conversations, and potential strategic alliances with bigger pharmaceutical players.

Geographic & Focused Expansion Founded in Massachusetts with multiple inflammatory disease programs, there may be attractive collaboration or regional partnering opportunities to expand development, manufacturing, or commercial reach beyond current indications.